Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 9/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 8/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24538772 | 0.86 | CYP2A6 (0.42) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL9603309 | 0.86 | CYP2A6 (0.42) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL20766587 | 0.80 | IDO1 (0.36) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL9967682 | 0.78 | CHRM2 (0.37) | ALOX5 | |
| SCHEMBL15047772 | 0.77 | CYP2D6 (0.44) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL16213682 | 0.76 | NPC1 (0.36) | ALOX5 | |
| SCHEMBL17929805 | 0.76 | ALOX5 (0.30) | ALOX5 | |
| SCHEMBL246123 | 0.76 | CYP2A6 (0.42) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL9967681 | 0.76 | ALDH1A1 (0.43) | CYP2A6CYP2C19CYP2C9CYP1A2ALOX5 | |
| SCHEMBL30704427 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2021-04-20 | — | — | US | disclosed |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20170319594-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2017-11-09 | — | — | US | disclosed |
| US-9744176-B2 | Therapeutic uses of novel thienopyrimidine derivatives | SANOFI (FR) | 2017-08-29 | — | — | US | disclosed |
| US-9744176-B2 | Therapeutic uses of novel thienopyrimidine derivatives | SANOFI (FR) | 2017-08-29 | — | — | US | disclosed |
| US-20150352124-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2015-12-10 | — | — | US | disclosed |
| US-9115140-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2013-10-03 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | CYP2A6 983/4885CYP2D6 1688/4885CYP2B6 1356/4885 |
| US-20150352124-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CYP2A6 309/4885CYP2D6 19/4885CYP2B6 37/4885 |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CYP2A6 172/4885CYP2D6 12/4885CYP2B6 19/4885 |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CYP2A6 144/4885CYP2D6 10/4885CYP2B6 18/4885 |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | CYP2A6 64/4885CYP2D6 8/4885CYP2B6 11/4885 |
| US-20170319594-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CYP2A6 172/4885CYP2D6 12/4885CYP2B6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.